SLU-PP-332 and BAM15 —
Metabolic Activation at the Nuclear Level

SLU-PP-332

Developed by: Washington University School of Medicine, St. Louis

Activates ERRα/ERRγ — the same nuclear transcription factors upregulated by endurance exercise — driving mitochondrial biogenesis and oxidative metabolism

• Activates ERRα and ERRγ — master regulators of mitochondrial biogenesis and oxidative phosphorylation gene expression
• Upregulates PGC-1alpha co-activation — the central driver of exercise-induced mitochondrial adaptation
• Promotes fast-to-slow muscle fiber type transition (oxidative phenotype)
• Improves endurance capacity and aerobic metabolism in preclinical models
• Research stage: preclinical to early human — limited long-term human safety data

BAM15

Dissipates the proton gradient across the inner mitochondrial membrane, uncoupling oxidative respiration from ATP synthesis — forcing cells to burn more substrate

• Mitochondrial proton gradient uncoupling — redirects respiratory energy from ATP production to heat
• Increases basal metabolic rate and total fuel consumption
• Promotes fatty acid oxidation — fat is the preferred substrate under uncoupled conditions
• More mitochondria-selective than earlier uncouplers (DNP) — reduced systemic toxicity profile in preclinical models
• Research stage: preclinical to early human — long-term human safety profile still being characterized

SLU-PP-332: ERRα/ERRγ Nuclear Receptor Agonism

Estrogen-related receptors alpha and gamma (ERRα, ERRγ) are orphan nuclear receptors — transcription factors without a well-characterized endogenous ligand — that function as master regulators of mitochondrial biogenesis and oxidative metabolism. They are among the primary transcription factors upregulated during endurance exercise training, and their downstream targets include PGC-1alpha (the central coactivator of mitochondrial biogenesis), genes encoding electron transport chain components, and the full suite of adaptations associated with an oxidative, endurance-trained metabolic phenotype. SLU-PP-332 is a potent synthetic agonist for both ERRα and ERRγ — it binds these receptors and activates their transcriptional programs, producing metabolic gene expression changes that mirror those induced by sustained endurance training. In animal models, SLU-PP-332 increased running endurance and drove fast-to-slow muscle fiber type transitions — the hallmark adaptation of aerobic training — without physical exercise.

BAM15: Mitochondrial Proton Gradient Uncoupling

Cellular energy production relies on the proton gradient across the inner mitochondrial membrane — protons pumped out by the electron transport chain flow back in through ATP synthase, driving ATP production. Protonophores like BAM15 provide an alternative proton channel across the membrane, short-circuiting this gradient and dissipating it as heat rather than ATP. The result is that the mitochondria must oxidize more substrate (primarily fatty acids) to maintain cellular function — metabolic rate increases, fat oxidation increases, and the futile cycling of the uncoupled proton gradient burns additional calories without changing physical activity levels. BAM15 is more mitochondria-selective than older protonophores like DNP (2,4-dinitrophenol), which had a narrow therapeutic window and significant toxicity risk. BAM15's selectivity profile is more favorable, though it is still a pharmacologically active metabolic agent that requires appropriate clinical oversight.

The Combination Logic

SLU-PP-332 and BAM15 are combined because they activate metabolic fuel consumption from complementary angles. SLU-PP-332 drives the genetic adaptation — more mitochondria, greater oxidative capacity, a cellular environment primed for fat oxidation. BAM15 drives the acute metabolic activation — increased substrate consumption through proton gradient uncoupling, with fat as the primary fuel. SLU-PP-332 builds the infrastructure; BAM15 puts it to work. The combined formulation (100mcg SLU-PP-332 / 15mg BAM15 per capsule) is designed to deliver both mechanisms simultaneously.

Important Context: Novelty and Human Data

The mechanistic basis for both compounds is well-established in preclinical research. Human studies are ongoing and accumulating. SLU-PP-332 and BAM15 do not yet have the depth of human clinical data that compounds like BPC-157, CJC-1295/Ipamorelin, or Sermorelin have accumulated over years of use. Patients pursuing these compounds should understand they are operating near the frontier of metabolic pharmacology — with correspondingly more uncertainty about long-term effects, optimal dosing, and individual response variation. This is why provider consultation is particularly important for these compounds.

Patients with Physically Limited Exercise Capacity

Patients who cannot exercise at levels sufficient to drive meaningful mitochondrial adaptation — due to injury, illness, disability, or severe deconditioning — may find SLU-PP-332's ERR agonism provides metabolic adaptations that physical training cannot. This is among the most clinically grounded use cases for an exercise-mimetic compound.

Metabolic Optimization Patients Seeking Novel Mechanisms

Patients already using NAD+, MOTS-C, or other mitochondrial compounds who want to add ERR nuclear receptor agonism as a distinct and non-overlapping mechanism. SLU-PP-332 targets transcription factor activation upstream of the pathways those compounds address.

Athletes Seeking Aerobic Adaptation Amplification

Endurance athletes or high-volume training patients who want to amplify the ERR-driven adaptations their training is already producing. SLU-PP-332 activates the same nuclear receptor program that endurance exercise activates — using both simultaneously may accelerate the rate of aerobic adaptation.

Early-Adopter Longevity Patients

Patients engaged with longevity optimization who specifically want access to compounds at the active research frontier — understanding that the trade-off for novelty is less established long-term human data. These patients are typically sophisticated about risk stratification, committed to provider oversight, and monitoring biomarkers regularly.

Available Formulations

Two capsule formats: the SLU-PP-332/BAM15 combination capsule (100mcg SLU-PP-332 / 15mg BAM15, 30-count, $196.00) for dual-mechanism activation, and the SLU-PP-332 standalone capsule (250mcg, 30-count, $301.00) for higher-dose ERR agonism without BAM15.

Dosing Approach

Because human dosing data is still accumulating, dosing is typically conservative and individualized. Your provider will establish the appropriate dose and frequency. Standard preclinical-to-human dosing translation suggests once-daily oral administration; BAM15 timing considerations may favor pre-workout or morning administration to align metabolic activation with periods of activity.

Cycle Structure

Given the novelty of these compounds, shorter initial cycles with careful monitoring are standard practice. Providers typically start with 4–6 week evaluation cycles before extending protocols. Lab monitoring at baseline and at cycle completion helps characterize individual metabolic response.

Stacking Considerations

SLU-PP-332 pairs logically with MOTS-C (complementary mitochondrial biogenesis pathways — ERR transcription factor activation alongside AMPK signaling), with NAD+ (electron transport chain cofactor support for increased mitochondrial activity), and with Elamiretide for comprehensive mitochondrial optimization. Stacking with BAM15 already included in the combination capsule should be discussed with your provider.

SLU-PP-332 / BAM15 Combination Capsule — 30 Count

SLU-PP-332 100mcg / BAM15 15mg per capsule. Dual-mechanism metabolic activation: ERRα/ERRγ nuclear receptor agonism paired with mitochondrial proton uncoupling. Once-daily oral capsule. Novel compounds — provider oversight essential.

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping

SLU-PP-332 250mcg Capsule — 30 Count

Higher-dose ERRα/ERRγ agonism without the BAM15 mitochondrial uncoupler component. For patients targeting nuclear receptor activation specifically, or those for whom BAM15 is not indicated. Once-daily oral capsule.

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping